Table 4.
Genotype frequencies of polymorphisms of EGFR gene in ESRD patients undergone kidney transplantation and controls.
| SNP | Genotype | Control | KT | Models | OR (95% CI) | p Value |
|---|---|---|---|---|---|---|
| n (%) | n (%) | |||||
| rs1140475 | C/C | 255 (88.2%) | 315 (90.8%) | Codominant1 | 0.74 (0.44–1.23) | .25 |
| T/C | 34 (11.8%) | 31 (8.9%) | Codominant2 | NA (0.00–NA) | 1.00 | |
| T/T | 0 (0%) | 1 (0.3%) | Dominant | 0.76 (0.45–1.26) | .28 | |
| Recessive | NA (0.00–NA) | .28 | ||||
| Log-additive | 0.79 (0.48–1.30) | .35 | ||||
| rs2293347 | G/G | 128 (44.3%) | 153 (44.1%) | Codominant1 | 0.97 (0.70–1.35) | .86 |
| A/G | 132 (45.7%) | 153 (44.1%) | Codominant2 | 1.18 (0.70–2.01) | .54 | |
| A/A | 29 (10%) | 41 (11.8%) | Dominant | 1.01 (0.74–1.38) | .96 | |
| Recessive | 1.20 (0.73–2.00) | .47 | ||||
| Log-additive | 1.05 (0.83–1.32) | .71 | ||||
| rs1050171 | G/G | 221 (76.5%) | 264 (76.1%) | Codominant1 | 1.04 (0.71–1.51) | .85 |
| A/G | 63 (21.8%) | 78 (22.5%) | Codominant2 | 0.84 (0.24–2.92) | .78 | |
| A/A | 5 (1.7%) | 5 (1.4%) | Dominant | 1.01 (0.70–1.46) | .96 | |
| Recessive | 0.87 (0.25–3.04) | .82 | ||||
| Log-additive | 1.00 (0.71–1.39) | .99 | ||||
| rs6965469 | C/C | 179 (62.1%) | 233 (67.3%) | Codominant1 | 0.79 (0.56–1.10) | .16 |
| T/C | 101 (35.1%) | 103 (29.8%) | Codominant2 | 0.96 (0.37–2.48) | .93 | |
| T/T | 8 (2.8%) | 10 (2.9%) | Dominant | 0.81 (0.58–1.12) | .21 | |
| Recessive | 1.05 (0.41–2.70) | .92 | ||||
| Log-additive | 0.85 (0.64–1.14) | .28 |
EGFR: epidermal growth factor receptor; ESRD: end stage renal disease; KT: kidney transplantation.